Unnatural Products has filed a notice of an exempt offering of securities to raise $18,851,017.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Unnatural Products is raising $18,851,017.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Cameron Pye played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Unnatural Products
Unlocking the potential of macrocycle drug discovery through machine learning and massively parallel synthesis. We’re a California-based biotech company using our platform to tackle the hard targets that will change the future of medicine. Founded by macrocycle pioneers whose academic work uncovered how Nature’s macrocycles work, UNP is a team of passionate scientists, engineers, and experienced drug developers. Our AI-enhanced platform creates entirely new drugs by engineering synthetic molecules to mimic nature’s macrocycles. Our platform produces passively permeable, macrocyclic peptides that access and address traditionally undruggable targets.
To learn more about Unnatural Products, visit http://www.unnaturalproducts.com/
Contact:
Cameron Pye, Chief Executive Officer
408-788-3574
https://www.linkedin.com/in/cpye/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.